August 20th 2025
Powering learnings of the dark genome to tackle disease at its source.
Magellan AI Identifies and Optimizes Molecules Beyond the Public Domain
August 6th 2025Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.
Computational Chemistry in Drug Discovery: Q&A with Dr. Peter Tummino
August 4th 2025Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.
Navigating Uncertainty with AI: Building Trust in the Way Forward
July 29th 2025Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges
July 25th 2025A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.
Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson
July 1st 2025Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.